Abstract Search

ea0052p36 | (1) | UKINETS2017

Phase 1/2 open-label trial to assess the safety and preliminary efficacy of ¹⁷⁷Lu-OPS201 as peptide receptor radionuclide therapy in patients with somatostatin receptor-positive, progressive neuroendocrine tumours

Nicolas Guillaume , Baum Richard , Herrmann Ken , Lassmann Michael , Hicks Rodney , Haug Alexander , Navalkissoor Shaunak , Oberwittler Heike , Wang Tiffany , Wild Damian

Introduction: Peptide receptor radionuclide therapy (PRRT) with radiolabelled somatostatin receptor (SSTR) agonists is highly effective and has become an integral part of neuroendocrine tumour (NET) treatment. However, tumour uptake and tumour-to-tissue dose ratios may be higher with radiolabelled SSTR antagonists than agonists. OPS201 (DOTA-JR11) is a very promising next-generation SSTR antagonist selective for SSTR2 (expressed by NETs). This phase 1/2, international, single-...

0 shares

Endocrine Abstracts

Phase 1/2 open-label trial to assess the safety and preliminary efficacy of ¹⁷⁷Lu-OPS201 as peptide receptor radionuclide therapy in patients with somatostatin receptor-positive, progressive neuroendocrine tumours

BiosciAbstracts

Endocrine Abstracts

Phase 1/2 open-label trial to assess the safety and preliminary efficacy of 177Lu-OPS201 as peptide receptor radionuclide therapy in patients with somatostatin receptor-positive, progressive neuroendocrine tumours

BiosciAbstracts

Phase 1/2 open-label trial to assess the safety and preliminary efficacy of ¹⁷⁷Lu-OPS201 as peptide receptor radionuclide therapy in patients with somatostatin receptor-positive, progressive neuroendocrine tumours